

## GEMFIBROSIL

**Class:** Antilipemic Agent, Fibric Acid

**Indications:** Treatment of hypertriglyceridemia in Fredrickson types IV and V hyperlipidemia for patients who are at greater risk for pancreatitis and who have not responded to dietary intervention; to reduce the risk of CHD development in Fredrickson type IIb patients without a history or symptoms of existing CHD who have not responded to dietary and other interventions (including pharmacologic treatment) and who have decreased HDL, increased LDL, and increased triglycerides

**Available dosage form in the hospital:** 600MG TAB

**Dosage:**

**Hyperlipidemia/hypertriglyceridemia:** Oral: 600 mg twice daily; administer 30 minutes before breakfast and dinner

**Renal Impairment:**

-Mild-to-moderate impairment: Use caution; deterioration of renal function has been reported in - patients with baseline serum creatinine >2 mg/dL

-Severe impairment: Use is contraindicated

-Hemodialysis: Not removed by hemodialysis; supplemental dose is not necessary.

**Hepatic Impairment**

Use is contraindicated.

**Common side effect:** Cardiovascular: Atrial fibrillation (1%)

Central nervous system: Fatigue (4%), vertigo (2%). Dermatologic: Eczema (2%), rash (2%)

Gastrointestinal: Abdominal pain (10%), nausea/vomiting (3%)

**Pregnancy Risk Factor:** C